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Background: The German Health Interview and Examination Survey for Adults (DEGS) is part of the recently
established national health monitoring conducted by the Robert Koch Institute. DEGS combines a nationally
representative periodic health survey and a longitudinal study based on follow-up of survey participants. Funding is
provided by the German Ministry of Health and supplemented for specific research topics from other sources.
Methods/design: The first DEGS wave of data collection (DEGS1) extended from November 2008 to December
2011. Overall, 8152 men and women participated. Of these, 3959 persons already participated in the German
National Health Interview and Examination Survey 1998 (GNHIES98) at which time they were 18–79 years of age.
Another 4193 persons 18–79 years of age were recruited for DEGS1 in 2008–2011 based on two-stage stratified
random sampling from local population registries. Health data and context variables were collected using
standardized computer assisted personal interviews, self-administered questionnaires, and standardized
measurements and tests. In order to keep survey results representative for the population aged 18–79 years, results
will be weighted by survey-specific weighting factors considering sampling and drop-out probabilities as well as
deviations between the design-weighted net sample and German population statistics 2010.
Discussion: DEGS aims to establish a nationally representative data base on health of adults in Germany. This
health data platform will be used for continuous health reporting and health care research. The results will help to
support health policy planning and evaluation. Repeated cross-sectional surveys will permit analyses of time trends
in morbidity, functional capacity levels, disability, and health risks and resources. Follow-up of study participants will
provide the opportunity to study trajectories of health and disability. A special focus lies on chronic diseases
including asthma, allergies, cardiovascular conditions, diabetes mellitus, and musculoskeletal diseases. Other core
topics include vaccine-preventable diseases and immunization status, nutritional deficiencies, health in older age,
and the association between health-related behavior and mental health.
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Age group (yrs) N N Response N Response
18–29 1073 19a 1054 40%
30–39 1014 427 49% 587 40%
40–49 1539 901 63% 638 44%
50–59 1592 928 69% 664 46%
60–69 1537 867 73% 670 47%
70–79 1233 653 65% 580 38%
18–79 7988 3795 64% 4193 42%
80–91 164 164 38%
18–91a 8152 3959 62% 4193 42%
aGNHIES98 participants were 28–91 years of age at the time of DEGS1.
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In Germany, several health interview and examination
surveys have been carried out since 1984. These surveys
addressed different subsets of the population and were
conducted at irregular intervals. In the framework of the
German Cardiovascular Prevention Study (GCP), resi-
dents of former West Germany 25–69 years of age were
surveyed in three independent consecutive surveys con-
ducted in 1984–86 (n = 4790), 1987–89 (n = 5335), and
1990–91 (n = 5311). The surveys were restricted to the
population in private households and to those who could
sufficiently speak German [1]. In 1991–92, the Survey
East was conducted, in order to provide comparable
health data for adults 18–79 years residing in private
households of former East Germany. Data of the Survey
East and the 1990–91 GCP survey were pooled for ana-
lyses of health data in the reunified Germany. Nearly a
decade later, the German National Health Interview
and Examination Survey 1998 (GNHIES98) conducted
under the auspices of the Robert Koch Institute (RKI)
was the first nationally representative health survey of
non-institutionalized adults 18–79 years in reunified
Germany [2]. It opened the perspective for analyzing
regional differences in health trends in comparison to
the 1990–92 data [3]. In 2003–2006, the RKI con-
ducted the German Health Interview and Examination
Survey for Children and Adolescents (KiGGS). Includ-
ing a total of 17641 study participants, KiGGS estab-
lished a large nationally representative health database
for the non-institutionalized German population 0–
17 years of age [4].
In 2008, the German Ministry of Health commissioned
the RKI to implement a system of health studies for con-
tinuous health monitoring of the non-institutionalized
population [5]. Survey components include: (1) annual
health interview surveys (German Health Update,
GEDA) conducted in large representative and independ-
ently drawn samples of the population 18 years and
older, (2) a national cohort study of children and adoles-
cents in Germany based on continuous follow-up of the
KiGGS study population, (3) periodically repeated inter-
view and health examination surveys of the population
18–79 years of age (German Health Interview and
Examination Survey for Adults, DEGS). We here
describe the design, objectives and implementation of
the first wave of data collection in DEGS (DEGS1),




DEGS is primarily designed as a periodically repeated
national health interview and examination survey of
adults in Germany. The target population comprisesadults 18–79 years of age with permanent residence in
Germany according to local population registries. In
order to lay the ground for longitudinal studies, persons
who had participated in the 1998 national health inter-
view and examination survey (GNHIES98) were invited
to take part in DEGS1, provided they had agreed to be
recontacted and were still contactable [6]. Representa-
tiveness of DEGS1 as a cross-sectional survey is main-
tained by extending the population sample based on a
two-stage sampling procedure according to power ana-
lyses and sample size estimations as described below.
The implementation of DEGS1 conforms to the princi-
ples outlined in the Declaration of Helsinki [7] and to the
German Federal Data Protection Act. The DEGS1 study
protocol was consented with the Federal and State Com-
missioners for Data Protection and approved by the
Charité-Universitätsmedizin Berlin ethics committee in
September 2008 (No. EA2/047/08). Participants provided
written informed consent prior to the interview and
examination.Study population
Overall 17410 persons, of whom N=6402 or 37% were
GNHIES98 participants, were invited to participate in
DEGS1. After excluding non-deliverable survey contacts,
persons unable to provide written informed consent and
persons with insufficient German language skills, the
overall net sample consisted of 16305 adults, of whom
N=6358 or 39% were GNHIES98 participants. Overall,
8152 adults (4283 women; 3869 men) participated in
DEGS1. Total numbers of the study population and re-
sponse rates are summarized by age group and
GNHIES98 participation status in Table 1. Response
rates were consistently higher among GNHIES98 partici-
pants compared to newly sampled individuals.
Both interview and examination data are available for
89% of the study population (N= 7238; 3765 women,
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(N= 914; 518 women, 396 men) have interview data
only, because they were unable or unwilling to come to
one of the local study centers. Cross-sectional and trend
analyses will be restricted to 7988 DEGS1 participants
18 to 79 years of age, with examination as well as inter-
view data available for 7116 of these. Longitudinal stud-
ies will include a total of 3959 persons 28–91 years of
age who participated in DEGS1 as well as in the
GNHIES98.
Sampling procedure
The DEGS1 sampling protocol was developed in co-
operation with the Leibniz Institute for the Social
Sciences (GESIS), Mannheim, Germany [8]. Like previ-
ous German health interview and examination surveys
[1,2,4] DEGS1 is based on two-stage stratified cluster
sampling. Primary sampling units (PSUs) are the com-
munities. PSUs were sampled from a list of German
communities stratified according to districts and the BIK
classification system, which takes into account the grade
of urbanization, regional population density, and admin-
istrative borders [9]. Sampling was done with probability
proportional to community size using the Cox procedure
for controlled rounding [10]. Selected metropolitan areas
were generally represented by several PSUs. Selected
communities with less than 1000 inhabitants were com-
bined with neighboring small communities to form a
single PSU. Within PSUs, random samples of indivi-
duals, stratified by 10-year age groups, were drawn from
local population registers.
Since DEGS1 included GNHIES98 participants, the
DEGS1 PSU sample had to build upon a total of 120
PSUs previously sampled for the 1998 survey. In order
to remain representative at the population level, add-
itional PSUs (N= 60) were sampled. In newly added
PSUs, all participants were newly sampled. Within
GNHIES98 PSUs, only newly recruited individuals are
included in the age group 18–28 years due to the aging
of the GNHIES98 cohort by 10–14 years. Persons
30 years and older were sampled as necessary, in order
to replace the number of participants expected to de-
cline participation in DEGS1 or to be lost to follow-up.
The number of newly sampled PSUs and individuals per
PSU was determined by statistical power and sample size
considerations as described below.
Statistical power and sample size calculations
Given the cluster design, simple variance estimates of
prevalence estimates will underestimate total variability
and hence estimation error, because individuals within
PSUs can be assumed to show greater similarities than
individuals randomly selected from the entire population
of Germany. The increase in estimation error isquantified by the design effect (Deff ). Total sample size
needs to be increased in proportion to Deff to attain the
same level of precision as in simple random sampling
[11]. Deff depends on the average number of individuals
within PSUs (m) and the degree of similarity within clus-
ters which is estimated by the intra class correlation co-
efficient (ICC): Deff= 1+ ICC(m-1) [12]. It is therefore
more efficient to increase the total number of PSUs ra-
ther than m, in order to keep the total sample size as
small as possible. Reasonably precise estimation of a sex
and 10-year-age group–specific prevalence of 1% (95%
CI to be attained: 0.5–2.1%) would require a total sample
size of about 7500. In this calculation, Deff is ignored as
the number of persons in a PSU within any sex-age-
group can be expected to be very small. Analyses of
GNHIES98 data showed that ICC can be assumed to
take on values between 0.005 and 0.036. Based on the
experience that survey logistics permit the examin-
ation of 40–50 persons per PSU, design effects would
be 4–15% higher with 50 instead of 40 persons seen
per PSU. The required precision could most efficiently
be reached based on a total number of 180 PSUs and
an average of m= 42 persons seen per PSU, yielding a
total sample size of 180 × 42 = 7560 [8]. This sample
size also proved to provide 90% power to detect a 3%
change in overall obesity prevalence in analyses for
time trends at the 5% significance level based on two-
sided tests [13].Recruitment of the study population
Eligible persons were invited to participate in the survey
by letter. An information booklet illustrated the study
objectives, procedures and logistics. A response card was
enclosed to fill in telephone numbers and preferred con-
tact times. Participants were offered a small monetary
incentive.
Invitation letters were sent approximately five weeks
prior to the survey visit. In order to optimize response
rates, survey activities were announced in local newspa-
pers, and if possible, on local television and radio sta-
tions. In addition, small survey reports were published at
regular intervals in national medical and public health
journals. Persons willing to participate were contacted
by telephone for scheduling and further information. A
confirmation letter including the time of the appoint-
ment, location plan, and preparatory instructions was
sent thereafter. Persons with appointments in the morn-
ing were asked to keep an overnight fast and not eat or
drink anything but water before blood testing, unless
they were diabetic. Persons with afternoon appointments
were asked to fast for at least four hours, unless they
were diabetic. Participants were asked to bring along
immunization records as well as the original containers
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used within 7 days prior to the survey appointment.
Personal contact was sought to persons who had not
responded to the invitation letter within four weeks. Ex-
clusion criteria (such as insufficient language proficiency
or inability to provide informed consent) were recorded.
Persons willing to participate but facing organizational
problems (e.g. lack of transportation, time constraints)
were offered transportation and flexible scheduling, such
as appointments early in the morning or in the evening.
Field logistics
Fieldwork in DEGS1 extended over three years. Data
collection started on November 25, 2008 and ended on
November 26, 2011. PSUs were successively visited by
two mobile study teams according to a random touring
schedule, in order to avoid a systematic bias of study
results by seasonal or time trends. Duration of stay at a
particular PSU was limited to one week. In order to in-
clude a sufficiently high number of study participants
per PSU, eligible persons had to be scheduled for
appointments ranging from 7:30 a.m. to 6:00 p.m. during
the week and from 7:30 a.m. to 10:30 a.m. on Saturdays.
Study teams consisted of specifically trained health
professionals, including a study physician and three
technicians. Interviews and examinations took place in
community-owned facilities that were rented for the
purpose of the survey.
Data collection procedures
Data collection in DEGS1 was based on: (1) a semi-
quantitative self-administered food frequency question-
naire (FFQ); (2) automated assessment of currently used
medications (AmEDa); (3) collection of urine and blood
samples; (4) standardized measurements and physical
performance tests (M/T); (5) a standardized physician-
administered computer-assisted personal interview
(CAPI); (6) a standardized self-filled questionnaire
(SFQ).
The FFQ questionnaire was mailed to study respon-
dents along with the confirmation letter. It included
instructions and examples for completion. Participants
were asked to take the completed questionnaire to the
survey appointment.
AmEDa as well as standardized measurements and
tests were conducted by study technicians. Unique prod-
uct identifiers (Pharmazentralnummer, PZN) on original
drug containers brought to the survey site were scanned
and automatically coded according to the latest version
of the WHO Anatomical Therapeutic Chemical (ATC)
Classification System [14]. Information on medication
source (doctor’s prescription, over-the–counter, family
medicine cabinet), indication, dose, frequency and dur-
ation of use, and intake within the past 24 hours wasdocumented. Missing information due to incomplete
matching (about 27% of scanned drugs) or missing ori-
ginal containers (about 1.5% of participants) was com-
pleted by telephone follow-up contacts and hand
searching.
Body weight and body height were measured in under-
wear with shoes removed. Waist and hip circumferences
were measured according to a standardized protocol.
Three consecutive automated blood pressure measure-
ments were taken on the right arm three minutes
apart with participants sitting and having been at rest
for five minutes.
Spot urine samples were collected and dipstick tested
on site. Venous blood samples were collected using
Vacutainer EDTA and gel tubes. The time of blood draw
and number of hours since last meal were recorded. Par-
ticipants who came in fasting were served a breakfast or
snack thereafter. Blood was centrifuged and separated.
Serum specimens as well as urine specimens were ali-
quoted and stored at −40°C within one hour. EDTA
whole blood tubes were shaken and kept in the original
collection tubes at 4°C. A 100 μl whole blood aliquot
intended for folate analysis was hemolyzed under light
protection and stored at −40°C. A full blood count was
performed on site. Additional whole blood, serum and
urine specimens were transported by car at −40°C at the
end of each survey week for further analysis and storage
at the central epidemiology laboratory unit at the Robert
Koch Institute, Berlin. Clinical chemistry and allergic
sensitization analyses were performed within 6–8 weeks.
Specific analyses and confirmatory tests relating to the
diagnosis of infectious diseases were commissioned to
reference laboratories. Extra serum, urine and whole
blood aliquots were stored at −40°C.
Applying the CAPI, study physicians obtained a
detailed medical history including family history. The
interview was administered in German language, hence
participants had to be sufficiently proficient in speaking
and understanding German. Self-administered question-
naires filled in at the survey site were available in differ-
ent languages (German, Turkish, Serbo-Croatian,
Russian, English). Foreign language versions were offered
to participants with German as a foreign language who
were able to communicate in German, but had limited
capacities for reading and writing in German. Different
versions of the questionnaire were used for the popula-
tion of working age (up to 64 years of age) and for
persons 65 years and above. A short version of the
self-administered questionnaire restricted to core ques-
tions was offered to those who lacked the strength or
time to answer the full-length questionnaire.
Completing the entire survey program required an
average of three hours. GNHIES98 participants who had
moved outside their PSU and were unable to come to
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assisted telephone interview (CATI) covering CAPI
questions and to answer a self-administered postal
questionnaire.
Objectives
DEGS1 aims to analyze health status, health risks and
resources, functional capacity levels, and disability in the
German adult population. Prevalence estimates will be
obtained and time trends will be analyzed in comparison
with data from the GNHIES98. Changes in health status
and risk factors over time at the individual level will be
studied among DEGS1 participants who already took
part in the GNHIES98. Major study objectives include:
(1) To estimate the prevalence of diseases and risk
factors with high public health impact and to
identify differences according to socio-demographic
characteristics, region of residence as well as
changes over time;
(2) To analyze data on medication use and health care
services utilization with regard to aspects of
treatment effectiveness and quality of care;
(3) To investigate the association between mental
health, physical health, and health-related behavior;
(4) To study patterns and determinants of co- and
multimorbidity in the population 65 years and older
in association with functional capacity levels,
disability and health-related quality of life;
(5) To analyze allergic sensitization patterns and
associations with manifest allergic disease in the
population;
(6) To assess nutritional health risks and states of
nutritional deficiency based on semiquantitative
assessment of dietary habits and serum
concentrations of various micronutrients
(25-hydroxyvitamin D, vitamin B 12, iron, and
ferritin in serum; serum and erythrocyte folate;
urinary sodium excretion);
(7) To estimate iodine intake at the population level
based on urinary iodine excretion;
(8) To examine individual changes in health status and
cardiometabolic risk factors (e. g. body mass index;
glycosylated hemoglobin A1c, serum lipids)
over time.
Constructs and instruments
As summarized in Table 2, constructs and instruments
applied in DEGS1 were kept compatible to those used in
the GNHIES98 as far as possible. The CAPI covered a
total of 32 health conditions including hepatitis (A, B, C,
E), prevalent chronic diseases and cardiovascular events
(stroke, myocardial infarction). Participants were asked
whether a particular health condition was everdiagnosed by a physician, and if so, at what age or in
what year the diagnosis was first made, and whether the
condition required any current medical treatment or
medication use. Persons with a lifetime history of a par-
ticular disease were asked, whether the disease was still
present during the 12 months preceding the interview.
Disease specific information was also obtained.
In addition to self-reported morbidity, detailed infor-
mation on current medication surveyed by AmEDa, and
various objective health measures will contribute to
analyze health status and health risks in the adult popu-
lation. Infectious diseases and immunization status will
be evaluated based on self-reported childhood infections
and vaccinations, immunization records, and laboratory
test results. These include serum concentrations of anti-
body titers against several viruses and bacteria as well as
nucleic acid amplification testing for confirmatory diag-
nosis of hepatitis B and C in serum and diagnosis of
gonorrhea and chlamydia infections in urine. Medication
use and objective health measures will help to validate
self-reported chronic health conditions, to identify previ-
ously unknown disease and hidden health risks, and to
analyze patterns of co- and multimorbidity as well as
aspects of treatment effectiveness and quality of care. A
list of chronic health conditions covered in DEGS1 and
information available from interview and examination is
given in Table 3.
Information on other facets of health, such as somatic
symptoms and complaints, various aspects of mental
health, and subjective health was collected via self-
administered questionnaires based on standardized
instruments (Table 2). Self-administered questionnaires
also served to collect detailed information on reproduct-
ive history among women, a history of benign prostate
disease among men, injuries, and among persons 65 years
and older, a history of fractures and falls as well as fear
of falls.
Functional capacities were assessed by standardized
questionnaires (vision and hearing impairment) and
tests. Aerobic endurance fitness tests using submaximal
endurance bicycle ergometry were restricted to the study
population 18–64 years. Exclusion criteria were defined
using the translated version of the Physical Activity
Readiness Questionnaire (PARQ) [15]. Among persons
65 years of age and older, functional capacities relevant
to daily life activities were assessed (Table 2). Isometric
handgrip strength in both hands was measured while
participants were standing upright using the Smedley S
dynamometer. A simple test sequence was used to assess
balance (Romberg test, semi-tandem, tandem, one-leg
stand), lower leg muscle strength and coordination (five-
chair rise test), and mobility (Timed “Up & Go”). Cognitive
functioning was assessed using the digit symbol substitu-
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Table 3 Chronic health conditions and information available from health interviewa and examinationb in DEGS1
Health condition Information
Allergic disease
Allergic contact eczema; allergic rhinitis;
food allergy; atopic eczema; insect venom allergy;
urticarial; other
Medical history and family history; current treatment;
lifetime history of allergy testing and specific immunotherapy
Inhalation allergy screening tests, total serum IgE, allergen-specific
IgE antibody tests against 52 specific allergens (food, pollen, contact,
insect, inner room allergens)
Cardiovascular disease
Angina pectoris or other coronary heart disease Medical history, current treatment; angina episodes and related
hospitalizations, emergency room treatments, doctor visits during past
12 months; lifetime history of specific tests and surgical procedures
Myocardial infarction (MI) Medical history and family history; current treatment; number of
events; time of first and last MI; lifetime history of specific tests and
surgical procedures
Heart failure Medical history; current treatment; acute exacerbations and related
hospitalizations, emergency room treatments, doctor visits within
past 12 months
Peripheral artery disease Medical history; current treatment
Stroke Medical history and family history; current treatment; number of events,
time of first and last event
Cardiometabolic conditions
Diabetes mellitus Medical history including type of diabetes and family history; diagnosis
during pregnancy; current treatment; treatment following diagnosis;
presence of long-term diabetes complications; history of acute hyper-
or hypoglycemia and related hospitalizations, emergency room treatments,
doctor visits within past 12 months; self-monitoring of blood glucose;
time of last follow-up care (foot inspection, HbA1c assessment,
eye background exam)
HbA1c; serum concentrations of glucose, insulin, C-peptide, glycosuria,
ketonuria, microalbuminuria
Hypertension Medical history and family history; current treatment; self-monitoring;
last time of blood pressure measurement by health professional;
last self-measurement; history of hypertensive emergency and related
hospitalizations, emergency room treatments, doctor visits during
past 12 months
Blood pressure measurements
Dyslipidemia Medical history; current treatment; serum total cholesterol, LDL- and
HDL- cholesterol, triglycerides
Gout and hyperuricemia Medical history; current treatment; serum uric acid
Gastrointestinal disease
Gastric or duodenal ulcer; chronic inflammatory
bowel disease
Medical history; current treatment
Liver, gallbladder, pancreatic disease Medical history of hepatitis including type of hepatitis (A, B, C, E) and liver
cirrhosis; current treatment
Hepatitis immunoassay and PCR-based confirmatory test results for
hepatitis B and C
Serum transaminases (ALT, AST), cholestatic liver enzymes (AP, GGT),
lipase; bilirubinuria, urobilinogenuria
Malignant disease
Any type of cancer Medical history including type of malignancy; current treatment and
cancer follow-up
Mental health disordersc
Anxiety disorder; depression; burnout;
eating disorder
Medical history, current treatment
Musculoskeletal disease
Osteoarthritis Medical history and history of joint replacement; current treatment,
specialist care; joint pain; lower back pain
Rheumatoid arthritis Medical history; current treatment, specialist care; joint pain
cyclic citrullinated peptide (CCP) antibody testd
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Table 3 Chronic health conditions and information available from health interviewa and examinationb in DEGS1
(Continued)
Osteoporosis Medical history; type of current treatment and specialist care; lower
back pain, history of fractures and falls; fear of falls; lifetime history of
bone densitometry
Serum 25-hydroxyvitamin-D, calcium, phosphate, intact parathyroid
hormone
Neurologic disease
Epilepsy; Migraine; Medical history; current treatment
Parkinson’s disease
Parkinson’s disease
Kidney and urogenital tract disease
Renal insufficiency Medical history of renal insufficiency; current treatment
Serum creatinine and cystatin C; microalbuminuria, proteinuria
Benign prostate disease Lifetime history including time of diagnosis and history of prostate surgery
Gynecological conditions Lifetime history of hysterectomy and oophorectomy; benign conditions
Lower respiratory tract disease
Asthma; chronic bronchitis Medical history including type of asthma; current treatment; lifetime history
of asthma-related allergy testing and specific immunotherapy; asthma related
hospitalizations, emergency room treatments, doctor visits within past
12 months
Thyroid disease
Hyper-, hypothyroidism; other thyroid disease Medical history including type of thyroid disorder, thyroid surgery,
radioiodine treatment; current treatment
Thyroid volume; serum thyroid hormones and TSH, thyroid antibodies
(TPO, TGA)
aInformation from computer-assisted personal interviews (CAPI) except for history of benign prostate disease, gynecological conditions, history of falls and
fractures, and fear of falls (self-administered questionnaires).
bInformation from standardized measurements and laboratory tests.
cInformation collected in DEGS1 by CAPI, not related to additional information collected in the DEGS1 mental health study module (DEGS1-MH).
dCCP antibody testing was limited to the first year of data collection.
Abbreviations: ALT alanine aminotransferase, AP alkaline phospatase, AST aspartate aminotransferase, GGT gamma-glutamyl transferase, TGA thyreoglobulin
antibody, TPO thyroid peroxidase antibody, TSH thyroid stimulating hormone.
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(WAIS-III).
Health risks and resources covered in DEGS1 include
potentially modifiable behavioral risk factors (e.g. diet-
ary habits, tobacco use, and risky alcohol consumption),
environmental factors (e.g. living and working condi-
tions, social support, lay caregiving), socio-demographic
context variables, and health care services utilization.
The FFQ was self-developed and designed to estimate
the frequency and amounts of 53 food groups consumed
during the past 4 weeks. It was validated against two
non-consecutive 24 hour recalls and showed an overall
reasonable validity [16]. Compared to the FFQ applied
in the GNHIES98, the DEGS1 FFQ has more food items
and includes estimation of portion sizes, which permits
a more quantitative estimation of food intake. The
instruments also cover a different time frame. Alcohol
consumption and tobacco use were assessed by self-
developed questions already applied in the GNHIES98.
Validated German versions of established instruments
were additionally applied in DEGS1 to identify personswith risky drinking behavior or nicotine dependence.
Socio-demographic variables were assessed according to
standards recommended by the German Epidemiology
and Preventive Medicine Associations [17]. Education
questions meet the International Standard Classification
of Education (ISCED) [18].
DEGS1 Mental Health Study Module
A separate mental health study module (DEGS1-MH)
was implemented for in depth assessment of mental
health disorders, help-seeking behavior and cognitive
function. The data were collected using computer-
assisted face-to-face interviews administered by specific-
ally trained psychologists. DEGS1 participants were
asked for their consent to be recontacted for a study
center or at home appointment within four weeks after
the basic DEGS1 clinic visit.
The core instrument of DEGS1–MH is a computer-
assisted German version of the Munich Composite
International Diagnostic Interview (DIA-X/M-CIDI)
[19], a modified and translated version of the World
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tic Interview (CIDI) [20]. The CIDI is a fully struc-
tured interview for the assessment of mental disorders
according to the definitions and criteria of ICD-10
and DSM-IV. It consists of several sections tailored to
assess mood disorders (major depression, dysthymic
disorder, bipolar disorder); anxiety disorders (panic
disorder, specific phobias, agoraphobia, generalized
anxiety disorder, social phobia); post-traumatic stress
disorder; obsessive-compulsive disorder; substance use
disorders (alcohol abuse and dependence, abuse and
dependence of pharmaceuticals, nicotine dependence);
eating disorders; somatoform disorders (pain disorders,
undifferentiated somatoform disorder); psychotic
symptoms (screening without further differential diag-
nosis); treatment of mental disorders. The CIDI is a
diagnostic instrument intended for use in clinical
practice as well as in clinical and epidemiological re-
search. It is suitable for use in population-based stud-
ies to estimate the prevalence of mental disorders, to
assess severity of mental disorders and associated bur-
den of disease, and to analyze treatment patterns,
treatment barriers, and aspects of quality of care
[20,21].
Cognitive function was assessed with a neuropsycho-
logical test battery that covers important cognitive
domains such as episodic memory, working memory, ex-
ecutive function, and cognitive speed. The battery con-
sists of established cognitive tests that were used in
epidemiological studies before and were mostly derived
from widely-used test batteries such as the German ver-
sion of the CERAD battery [22,23].
The DEGS1-MH is carried out in close cooperation
between the Robert Koch Institute and the Institute of
Clinical Psychology and Psychotherapy, Center
of Clinical Epidemiology and Longitudinal Studies
(CELOS) at the Technische Universität Dresden. CELOS
was already commissioned to carry out the Mental
Health Module of the GNHIES98 [24,25]. This opens
the perspective for analyses of changes in the prevalence
of mental health problems as well as for longitudinal
analyses based on individuals participating in both
surveys.Assessment of non-response bias
Persons sampled and eligible for DEGS1 who declined
participation were asked to provide the reason for non-
participation. In addition, they were asked to fill in a
short questionnaire covering essential health-related
characteristics, such as self-rated health, history of long-
standing chronic illness, smoking habits, educational
background, and doctor visits. This will permit compari-
son of participants and non-participants with respect toage, sex, education, health status, health-related behav-
ior, and health care services utilization.
Data management and preparation for analysis
The DEGS1 data set will comprise approximately 2000
items per study participant. Data management has been
carried out in parallel with data collection based on
highly standardized and partly automated procedures for
data processing and plausibility checking. This will assist
in providing high quality and timely data. A final set of
key data was available for main pre-planned analyses
6 months after the completion of fieldwork. Data from
the DEGS1 survey wave will be made available to the
scientific community as a public use file in 2014.
In order to assure that estimates derived from DEGS1
are representative at the national level, two sets of sam-
ple weights were computed :one set for all participants
aged 18–79 years, one set for those with examination
data available. Sample weights adjust for different sam-
pling probabilities within the design strata and correct
for deviations between the design-weighted net sample
and German population statistics (December 31, 2010)
based on an iterative raking procedure using age, sex,
federal state of residence, community BIK classification
category, nationality (German yes/no), and education
level according to ISCED [18] using population statistics
dating from 2009. For GNHIES98 participants included
in DEGS1, the weighting procedure additionally includes
adjustments for the re-participation rate.
Quality assurance
The DEGS1 study operations manual contains standard
operating procedures (SOPs) for all DEGS1 interview
and examination components as well as internal and ex-
ternal quality control measures [8]. Members of the
study teams underwent an initial two-week training ses-
sion leading to accreditation. They were continuously
supervised and reassessed at 6-month intervals. Internal
quality control was carried out by senior RKI supervising
staff. Measures of internal quality assurance encom-
passed: regular field visits to the study teams, bimonthly
reviews of logbook entries for meeting requirements of
daily calibration procedures and transportation of blood
and urine specimens, continuous data checks for com-
pleteness and plausibility. External quality assurance was
carried out by specifically experienced scientists of the
Bremen Institute for Epidemiology and Prevention
Research (BIPS) based on field observation and data
audits.
Feed-back to study participants
Participants received immediate feed-back on clinically
relevant test results based on written summary reports
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study participants received a standardized letter sum-
marizing clinically relevant study results including clin-
ical chemistry, test results for hepatitis, chlamydia and
gonorrhea infections, specific allergy testing, body mass
index, blood pressure, thyroid volume, and physical fit-
ness. Study participants will also be informed about im-
munity status against poliomyelitis, measles, mumps,
and rubella as test results become available.
Collaborations
The DEGS1 steering committee at the Robert Koch
Institute welcomes collaborations with external research-
ers. Collaborations may relate to input of specific know-
how and professional expertise to analyses that were
given a particularly high level of priority and therefore
pre-planned to be completed within two years after
finishing fieldwork. Additional analyses will require a
research proposal, which will be reviewed by the
DEGS1 steering committee and the Robert Koch Insti-
tute Research Council in order to ensure data protec-
tion and privacy regulations, public health relevance,
data efficiency, and scientific quality. For further infor-
mation please visit the DEGS1 study homepage at
www.degs-studie.de.
Discussion
As part of the recently established continuous health
monitoring system in Germany, the first data collection
wave of the German Health Interview and Examination
Survey for Adults (DEGS1) was conducted by the Robert
Koch Institute between November 2008 and December
2011. The DEGS national health survey system is pri-
marily designed to provide nationally representative
health interview and examination data for the popula-
tion 18–79 years of age and to conduct analyses of time
trends in population health and disability. Interview and
examination data will be collected in periodically
repeated survey waves at 8-year intervals [6]. By includ-
ing a large number of persons who already participated
in a previous national health interview and examination
survey (GNHIES98), DEGS1 combines a national health
survey and a survey follow-up study. In order to keep
cross-sectional results of DEGS1 representative at the
national level, a number of measures were taken. First,
to compensate for attrition and aging of the GNHIES98
cohort, a sample of the population 18–79 years was
newly drawn from local population registries using a
two-stage stratified cluster sampling procedure. Sec-
ondly, results from DEGS1 cross-sectional analyses will
be weighted by survey-specific weights considering sam-
pling probabilities and non-response for newly drawn
participants as well as re-participation probability for
GNHIES98 participants.In DEGS1, a wide range of objective health measures
were collected based on highly standardized measure-
ments and tests including laboratory analyses. Auto-
mated medication assessment and coding provided
detailed and objective information on current medica-
tion use. It will hence be possible to verify self-reported
health conditions, to identify undetected cases of dis-
ease, and to evaluate current disease or risk factor
control in the population. High risk groups and health
inequalities will be identified based on analyses strati-
fied by sex, age, educational background, income, pro-
fessional and employment status, and region of
residence. Burden of disease will be assessed by analyz-
ing the association of morbidity and comorbidity with
functional impairment, subjective health, health-related
quality of life, and disability. In order to explore pre-
ventive potential, these associations will be further ana-
lyzed with respect to personal and environmental resources,
e.g. socio-demographic characteristics, health-related
behavior, level of perceived social support, health care ser-
vices utilization.
Results of trend analyses will be used to identify new
health risks, to evaluate the effectiveness of health pro-
grams and regulations at the population level (e.g. reduc-
tion of smoking rates; improved hypertension control),
and to validate absolute risk prediction models. Inter-
pretation of time trends will need to consider survey
data as well as additional information, such as trends in
cause-specific mortality, disease management program
enrollment, treatment patterns, ambulatory care sensi-
tive hospital admissions, and nursing care rates. As an
example, the prevalence of persons with known diabetes
mellitus is likely to have increased over time due to
aging of the population and increases in the prevalence
of major diabetes risk factors such as obesity. However,
improved awareness, treatment and survival may have
contributed to increases in prevalence as well. Further
insight will be gained from comparative analyses of time
trends in the prevalence of persons with known and un-
detected diabetes.
With respect to time trend analyses, concepts, indica-
tors, instruments and methods of data collection in
DEGS1 were kept the same as in prior national health
interview and examination surveys, in particular the
GNHIES98, as far as possible. There were certain limita-
tions to this. For example, there was a change in meth-
ods for measuring blood pressure and some biochemical
measures. Analyses of time trends will hence require
cross-calibration studies in some cases. Furthermore,
several constructs and instruments were newly added
in DEGS1. Health indicators have been continuously
reviewed and extended in close cooperation with health
policy makers and public health expert groups, in order
to permit harmonization with regional population-based
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from other countries. In order to improve the compar-
ability of results between countries, great efforts have
been undertaken at the EU and OECD level to
harmonize indicators and instruments and to rigorously
standardize the data collection process [26-29]. Areas of
ongoing work on indicators particularly relate to health
in older age [30].
DEGS1 response rates among newly recruited study
participants are considerably lower than response rates
in the GNHIES98 (42% vs. 62%). Declining response
rates in population-based health surveys have consist-
ently been reported from other European countries over
the past decade [31,32]. Selection bias resulting from se-
lective participation of healthier persons is a concern in
any population-based survey [33]. Survey results may
therefore underestimate the overall prevalence of
chronic diseases and disability compared to results from
claims data [34]. In addition, persons unable to provide
written consent and those with significant language bar-
riers were excluded from participation in DEGS1. Thus,
DEGS1 is likely to underrepresent adults living in insti-
tutions. To some extent, this may also be true for
persons with an immigration background, even though
sample weights encompass adjustment for nationality
(German yes/no). Careful non-response analyses will
be carried out based on available information from
official health statistics and non-response question-
naires with respect to nursing care enrollment and
institutionalization, non-German nationality, self-rated
health, history of long-standing chronic illness, smoking
habits, educational background, and health care services
utilization.
About half of the DEGS1 study population already
participated in a previous national health survey
(GNHIES98). This provides ten- to 12-year follow-up
data on nearly 4000 individuals. It will hence be possible
to analyze age- and sex-specific individual level changes
in many risk factors and health status indicators avail-
able from both surveys as presented in Table 2 [8,16-
18,35-66]. The DEGS survey panel will continuously
grow and timepoints of measurements will be added as
DEGS participants who agreed to be re-contacted will be
included in subsequent survey interview and examin-
ation waves. In between examination survey waves,
DEGS participants will be contacted by telephone and
postal questionnaires, in order to assess incident health
events and changes in health status and health-related
behavior. The panel will be continuously followed for
vital status and cause-specific death. Participants will be
asked for advance written permission for death certifi-
cate review, in order to assess cause-specific mortality.
Together, this growing data base will facilitate to study
trajectories of risk factors, chronic conditions, andhealth outcomes. In addition, extended follow-up will in-
crease absolute numbers for estimates of disease inci-
dence and prospective analyses using incident health
events and total or cause-specific deaths as outcome
measures [6].
In summary, data from DEGS1 and subsequent DEGS
survey waves will make essential contributions to the
surveillance of communicable as well as non-
communicable diseases in Germany. Data collected in
periodically repeated national health surveys of adults in
Germany will be used for continuous health reporting.
Findings will be relevant to health policy planning and
evaluation, public health research, and health informa-
tion of the lay public. Survey participants will be fol-
lowed for changes in health status and health outcomes.
Cross-sectional and longitudinal data will be entered in
a large health data platform for health and health care
services research.
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